Viral suppression after transition from nonnucleoside reverse transcriptase inhibitor‐ to dolutegravir‐based antiretroviral therapy: A prospective cohort study in Lesotho (DO‐REAL study)

OBJECTIVES: Since 2018, the World Health Organization has recommended dolutegravir (DTG)‐containing antiretroviral therapy (ART) for most people living with HIV. Country programmes across Africa have subsequently transitioned from other, mostly nonnucleoside reverse transcriptase inhibitor (NNRTI)‐b...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Jennifer A., Nsakala, Bienvenu L., Mokhele, Kuena, Rakuoane, Itumeleng, Muhairwe, Josephine, Urda, Lorena, Amstutz, Alain, Tschumi, Nadine, Klimkait, Thomas, Labhardt, Niklaus D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Short Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293184/
https://www.ncbi.nlm.nih.gov/pubmed/34632682
http://dx.doi.org/10.1111/hiv.13189

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293184/
https://www.ncbi.nlm.nih.gov/pubmed/34632682
http://dx.doi.org/10.1111/hiv.13189

Ejemplares similares